CN108530424B - 赖氨酸特异性脱甲基酶-1的抑制剂 - Google Patents

赖氨酸特异性脱甲基酶-1的抑制剂 Download PDF

Info

Publication number
CN108530424B
CN108530424B CN201810425583.0A CN201810425583A CN108530424B CN 108530424 B CN108530424 B CN 108530424B CN 201810425583 A CN201810425583 A CN 201810425583A CN 108530424 B CN108530424 B CN 108530424B
Authority
CN
China
Prior art keywords
optionally substituted
compound
pharmaceutically acceptable
acceptable salt
heterocyclyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201810425583.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108530424A (zh
Inventor
扬·K·陈
陶菲克·卡努尼
哲·聂
杰弗里·艾伦·斯塔福德
詹姆斯·马文·维尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Celgene Quanticel Research Inc
Original Assignee
Celgene Quanticel Research Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celgene Quanticel Research Inc filed Critical Celgene Quanticel Research Inc
Publication of CN108530424A publication Critical patent/CN108530424A/zh
Application granted granted Critical
Publication of CN108530424B publication Critical patent/CN108530424B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D519/00Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Polyamides (AREA)
CN201810425583.0A 2014-07-03 2015-06-29 赖氨酸特异性脱甲基酶-1的抑制剂 Expired - Fee Related CN108530424B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462020886P 2014-07-03 2014-07-03
US62/020,886 2014-07-03
CN201580047448.1A CN106795103B (zh) 2014-07-03 2015-06-29 赖氨酸特异性脱甲基酶-1的抑制剂

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201580047448.1A Division CN106795103B (zh) 2014-07-03 2015-06-29 赖氨酸特异性脱甲基酶-1的抑制剂

Publications (2)

Publication Number Publication Date
CN108530424A CN108530424A (zh) 2018-09-14
CN108530424B true CN108530424B (zh) 2021-10-01

Family

ID=55019883

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201810425583.0A Expired - Fee Related CN108530424B (zh) 2014-07-03 2015-06-29 赖氨酸特异性脱甲基酶-1的抑制剂
CN201580047448.1A Expired - Fee Related CN106795103B (zh) 2014-07-03 2015-06-29 赖氨酸特异性脱甲基酶-1的抑制剂

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201580047448.1A Expired - Fee Related CN106795103B (zh) 2014-07-03 2015-06-29 赖氨酸特异性脱甲基酶-1的抑制剂

Country Status (29)

Country Link
US (3) US9902719B2 (enExample)
EP (2) EP3164380B1 (enExample)
JP (2) JP6663866B2 (enExample)
KR (1) KR102475498B1 (enExample)
CN (2) CN108530424B (enExample)
AU (1) AU2015284383B2 (enExample)
BR (1) BR112017000043A2 (enExample)
CA (1) CA2954049A1 (enExample)
CL (1) CL2016003422A1 (enExample)
CO (1) CO2017000549A2 (enExample)
CY (1) CY1125127T1 (enExample)
DK (2) DK3511319T3 (enExample)
EA (2) EA033698B1 (enExample)
EC (1) ECSP17006821A (enExample)
ES (2) ES2907676T3 (enExample)
FI (1) FI3511319T3 (enExample)
HR (2) HRP20230595T1 (enExample)
HU (2) HUE058852T2 (enExample)
IL (2) IL249881B (enExample)
LT (2) LT3511319T (enExample)
MX (2) MX395534B (enExample)
PL (2) PL3164380T3 (enExample)
PT (2) PT3511319T (enExample)
RS (2) RS63074B1 (enExample)
SA (1) SA517380651B1 (enExample)
SG (2) SG11201610975RA (enExample)
SI (2) SI3164380T1 (enExample)
SM (2) SMT202200136T1 (enExample)
WO (1) WO2016003917A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3307909A1 (en) 2015-06-12 2018-04-18 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
WO2017013061A1 (en) 2015-07-17 2017-01-26 Oryzon Genomics, S.A. Biomarkers associated with lsd1 inhibitors and uses thereof
SG11201807965YA (en) 2016-03-15 2018-10-30 Oryzon Genomics Sa Combinations of lsd1 inhibitors for use in the treatment of solid tumors
ES3042059T3 (en) 2016-03-16 2025-11-18 Oryzon Genomics Sa Methods to determine kdm1a target engagement and chemoprobes useful therefor
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
EP3535420A1 (en) 2016-11-03 2019-09-11 Oryzon Genomics, S.A. Biomarkers for determining responsiveness to lsd1 inhibitors
DK3661510T3 (da) 2017-08-03 2025-01-02 Oryzon Genomics Sa Fremgangsmåder til behandling af adfærdsændringer
PE20211050A1 (es) * 2018-08-10 2021-06-04 Navire Pharma Inc Inhibidores de ptpn11
CN113365996B (zh) * 2019-02-01 2024-09-03 韩美药品株式会社 咪唑吡啶衍生化合物以及药物组成物
JP7532386B2 (ja) 2019-02-01 2024-08-13 ハンミ ファーマシューティカルズ カンパニー リミテッド イミダゾピリジン誘導体化合物及びその用途
JP7535797B2 (ja) 2019-03-20 2024-08-19 オリソン ヘノミクス,ソシエダ アノニマ 化合物バフィデムスタット(vafidemstat)などkdm1a阻害剤を使用した注意欠陥多動性障害の処置方法
SG11202109159VA (en) 2019-03-20 2021-10-28 Oryzon Genomics Sa Methods of treating borderline personality disorder
JP2022546908A (ja) 2019-07-05 2022-11-10 オリゾン・ゲノミクス・ソシエダッド・アノニマ Kdm1a阻害剤を使用した小細胞肺がんの個別化された処置のためのバイオマーカーおよび方法
US11360505B2 (en) 2020-02-11 2022-06-14 Simmonds Precision Products, Inc. Distributed network time synchronization
CN114105950B (zh) * 2020-08-31 2022-09-06 南京明德新药研发有限公司 吡唑类化合物及其应用
US20240199571A1 (en) * 2021-03-11 2024-06-20 Medshine Discovery Inc. Thiophene compound and application thereof
US20240216357A1 (en) * 2021-03-24 2024-07-04 Sichuan Huiyu Pharmaceutical Co., Ltd. Polycyclic compound and application thereof
CA3231846A1 (en) 2021-04-08 2022-10-13 Tamara Maes Combinations of lsd1 inhibitors for treating myeloid cancers
CN116102533A (zh) * 2021-11-11 2023-05-12 中国科学院上海药物研究所 一种芳杂环类化合物及其应用
JP2025516647A (ja) 2022-05-09 2025-05-30 オリゾン・ゲノミクス・ソシエダッド・アノニマ Lsd1阻害薬を用いる悪性末梢神経鞘腫(mpnst)の治療法
CN119497613A (zh) 2022-05-09 2025-02-21 奥莱松基因组股份有限公司 使用lsd1抑制剂治疗nf1-突变肿瘤的方法
WO2024110649A1 (en) 2022-11-24 2024-05-30 Oryzon Genomics, S.A. Combinations of lsd1 inhibitors and menin inhibitors for treating cancer

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1963188A1 (de) * 1969-12-17 1971-06-24 Bayer Ag Neue Cyanphenyl-1,4-dihydropyridinderivate
AU2002214546A1 (en) * 2000-09-29 2002-04-08 Cor Therapeutics, Inc. Bicyclic pyrimidin-4-one based inhibitors of factor xa
US7365069B2 (en) * 2002-04-10 2008-04-29 Bexel Pharmaceuticals Inc. Pyrimidone derivatives
JP2005170792A (ja) * 2002-11-22 2005-06-30 Mitsubishi Pharma Corp L−プロリン誘導体およびその医薬としての用途。
KR101146849B1 (ko) * 2003-12-11 2012-05-16 미쓰비시 타나베 파마 코퍼레이션 α-아미노산 유도체 및 그 의약 용도
WO2006073167A1 (ja) * 2005-01-07 2006-07-13 Ono Pharmaceutical Co., Ltd. ピロリジン誘導体
PL372332A1 (pl) * 2005-01-19 2006-07-24 ADAMED Sp.z o.o. Nowe związki, pochodne kwasu 3-fenylopropionowego
WO2006129181A2 (en) * 2005-06-03 2006-12-07 Orchid Research Laboratories Limited Preparation of 4-pyrimidone derivatives for treating inflammatory diseases
JP5155864B2 (ja) * 2005-09-01 2013-03-06 イーライ リリー アンド カンパニー 5−HT2C受容体アゴニストとしての6−アリールアルキルアミノ−2,3,4,5−テトラヒドロ−1H−ベンゾ[d]アゼピン
JP2007197324A (ja) * 2006-01-23 2007-08-09 Toray Ind Inc 2,4,5−置換−1,3−アゾール誘導体
US7652018B2 (en) 2006-08-15 2010-01-26 Wyeth Llc Imidazolidin-2-one derivatives useful as PR modulators
TW200815428A (en) * 2006-08-15 2008-04-01 Wyeth Corp Oxazolidone derivatives as PR modulators
PE20081803A1 (es) 2007-03-09 2008-12-11 Wyeth Corp Sintesis y caracterizacion de la forma ii polimorfica de 4-(2-(4,4-dimetil-2-oxooxazolidin-3-il)tiazol-4-il)benzonitrilo
CL2008002793A1 (es) * 2007-09-20 2009-09-04 Cgi Pharmaceuticals Inc Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras
WO2009132310A1 (en) * 2008-04-25 2009-10-29 Wisconsin Alumni Research Foundation Inhibitors of udp-galactopyranose mutase thwart mycobacterial growth
WO2011130515A1 (en) * 2010-04-14 2011-10-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Arylthiazolyl piperidines and related compounds as modulators of survival motor neuron (smn) protein production
WO2012009475A1 (en) * 2010-07-14 2012-01-19 Oregon Health & Science University Methods of treating cancer with inhibition of lysine-specific demethylase 1
EP2822946A1 (en) * 2012-03-06 2015-01-14 Lupin Limited Thiazole derivatives as alpha 7 nachr modulators
LT3080100T (lt) * 2013-12-11 2023-02-27 Celgene Quanticel Research, Inc. Lizinui specifinės demetilazės-1 inhibitoriai
KR20160115999A (ko) * 2014-02-14 2016-10-06 더 유니버시티 오브 브리티쉬 콜롬비아 치료제로서의 인간 안드로겐 수용체 dna-결합 도메인(dbd) 화합물 및 그의 사용 방법
DK3137169T3 (da) * 2014-05-01 2022-02-14 Celgene Quanticel Res Inc Hæmmere af lysin-specifik demethylase-1
FR3020945B1 (fr) 2014-05-16 2016-05-06 Oreal Composition pour colorer les fibres keratiniques comprenant une base d'oxydation et un coupleur heteroaryle particulier
PL3160956T3 (pl) * 2014-06-27 2020-11-30 Celgene Quanticel Research, Inc. Inhibitory demetylazy-1 specyficznej dla lizyny
CA2954060A1 (en) * 2014-07-03 2016-01-07 Celgene Quanticel Research, Inc. Inhibitors of lysine specific demethylase-1

Also Published As

Publication number Publication date
MX395534B (es) 2025-03-25
EP3511319A1 (en) 2019-07-17
EA033698B1 (ru) 2019-11-18
RS63074B1 (sr) 2022-04-29
HUE058852T2 (hu) 2022-09-28
FI3511319T3 (fi) 2023-07-20
AU2015284383A1 (en) 2017-02-02
US20180127408A1 (en) 2018-05-10
EP3164380A4 (en) 2018-07-18
MX376207B (es) 2025-03-07
CL2016003422A1 (es) 2017-11-10
EA201891526A3 (ru) 2019-05-31
MX2020010900A (es) 2022-09-13
SG11201610975RA (en) 2017-01-27
PT3164380T (pt) 2022-03-02
EA201891526A2 (ru) 2018-12-28
WO2016003917A1 (en) 2016-01-07
PT3511319T (pt) 2023-06-29
ES2907676T3 (es) 2022-04-26
HRP20220414T1 (hr) 2022-05-27
CN106795103B (zh) 2019-07-12
JP6663866B2 (ja) 2020-03-13
DK3164380T3 (da) 2022-03-28
DK3511319T3 (da) 2023-07-31
KR20170018100A (ko) 2017-02-15
EP3164380B1 (en) 2022-02-09
HRP20230595T1 (hr) 2023-09-15
CN108530424A (zh) 2018-09-14
SI3511319T1 (sl) 2023-10-30
IL249881B (en) 2020-01-30
CA2954049A1 (en) 2016-01-07
EP3511319B1 (en) 2023-05-03
JP2019108346A (ja) 2019-07-04
CY1125127T1 (el) 2024-02-16
SG10201802501RA (en) 2018-05-30
JP6768857B2 (ja) 2020-10-14
PL3511319T3 (pl) 2023-09-11
RS64423B1 (sr) 2023-09-29
MX2017000168A (es) 2017-05-01
LT3164380T (lt) 2022-06-27
ECSP17006821A (es) 2017-03-31
SI3164380T1 (sl) 2022-06-30
BR112017000043A2 (pt) 2018-07-17
IL272130A (en) 2020-03-31
IL272130B (en) 2021-03-25
HUE062558T2 (hu) 2023-11-28
EP3164380A1 (en) 2017-05-10
SA517380651B1 (ar) 2020-09-30
SMT202200136T1 (it) 2022-05-12
US20170129882A1 (en) 2017-05-11
IL249881A0 (en) 2017-03-30
AU2015284383B2 (en) 2019-04-18
SMT202300205T1 (it) 2023-09-06
US10100046B2 (en) 2018-10-16
CN106795103A (zh) 2017-05-31
CO2017000549A2 (es) 2017-04-20
ES2948782T3 (es) 2023-09-19
US9902719B2 (en) 2018-02-27
LT3511319T (lt) 2023-08-25
KR102475498B1 (ko) 2022-12-07
EA201790085A1 (ru) 2017-08-31
PL3164380T3 (pl) 2022-04-04
US20190002456A1 (en) 2019-01-03
JP2017525668A (ja) 2017-09-07

Similar Documents

Publication Publication Date Title
CN108530424B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
CN106659914B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
US10131664B2 (en) Inhibitors of lysine specific demethylase-1
CN106604997B (zh) 赖氨酸特异性脱甲基酶-1的抑制剂
AU2015311805A1 (en) Inhibitors of lysine specific demethylase-1
HK1230202B (en) Inhibitors of lysine specific demethylase-1
HK1230202A1 (en) Inhibitors of lysine specific demethylase-1

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20211001

CF01 Termination of patent right due to non-payment of annual fee